- Pfizer C3621001- A Phase 1 Study to evaluate the safety, pharmacokinetics, and pharmacodynamics of escalating doses and treatment intensification of a vaccine-based immunotherapy regimen-2 (VBIR-2) (PF-06936308) for advanced Non-Small Cell lung cancer and metastatic triple-negative breast cancer.
Non-Small Cell lung cancer and triple negative breast cancer
April 12, 2019